- Home
- QCRH vs IRON Comparison
QCRH vs IRON Comparison
Compare QCRH & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- IRON
- Stock Information
- Founded
- QCRH 1993
- IRON 2017
- Country
- QCRH United States
- IRON United States
- Employees
- QCRH N/A
- IRON N/A
- Industry
- QCRH Major Banks
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- IRON Health Care
- Exchange
- QCRH Nasdaq
- IRON Nasdaq
- Market Cap
- QCRH 1.4B
- IRON 1.4B
- IPO Year
- QCRH 1993
- IRON N/A
- Fundamental
- Price
- QCRH $89.89
- IRON $59.46
- Analyst Decision
- QCRH Buy
- IRON Strong Buy
- Analyst Count
- QCRH 3
- IRON 10
- Target Price
- QCRH $76.00
- IRON $72.00
- AVG Volume (30 Days)
- QCRH 78.4K
- IRON 431.6K
- Earning Date
- QCRH 10-23-2024
- IRON 11-12-2024
- Dividend Yield
- QCRH 0.27%
- IRON N/A
- EPS Growth
- QCRH 6.88
- IRON N/A
- EPS
- QCRH 6.88
- IRON N/A
- Revenue
- QCRH $341,805,000.00
- IRON N/A
- Revenue This Year
- QCRH N/A
- IRON N/A
- Revenue Next Year
- QCRH $10.78
- IRON N/A
- P/E Ratio
- QCRH $13.07
- IRON N/A
- Revenue Growth
- QCRH 5.07
- IRON N/A
- 52 Week Low
- QCRH $49.48
- IRON $25.60
- 52 Week High
- QCRH $93.72
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- QCRH 65.51
- IRON 58.39
- Support Level
- QCRH $76.80
- IRON $63.21
- Resistance Level
- QCRH $93.72
- IRON $68.73
- Average True Range (ATR)
- QCRH 2.64
- IRON 3.49
- MACD
- QCRH 0.65
- IRON 0.52
- Stochastic Oscillator
- QCRH 77.36
- IRON 61.25
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.